Twenty seven generic manufacturing companies have signed agreements with Medicines Patent Pool (MPP), a UN-backed public health organisation, to produce low-cost versions of Covid-19 antiviral medication for 105 low and middle-income countries, a statement by MPP says.
MPP was founded in 2010 by Unitaid, a global health initiative.
The non-exclusive sublicences allow generic manufacturers to produce the raw ingredients for molnupiravir and/or the finished drug itself.
“We are encouraged by the large number of new and existing partners that have moved quickly to secure a sublicence for molnupiravir through MPP,” said Charles Gore, MPP executive director.
The agreements are the result of the voluntary licencing deal signed by MPP and MSD, a trade name of Merck & Co, in October to facilitate affordable global access for molnupiravir that MSD is developing in partnership with Ridgeback Biotherapeutics.
The manufacturers span 11 countries: Bangladesh, China, Egypt, Jordan, India, Indonesia, Kenya, Pakistan, South Africa, South Korea and Vietnam.
“This is a critical step toward ensuring global access to an urgently needed COVID-19 treatment and we are confident that, as manufacturers are working closely with regulatory authorities, the anticipated treatments will be rapidly available in LMICs,” Mr Gore said.
